NOV 02, 2016 8:51 AM PDT

Mutation Allows Liver Cancer Cells to Escape Limbo

WRITTEN BY: Xuan Pham

Increasingly, doctors are recognizing the impact of genetic differences on disease and treatment outcomes. This realization is impetus behind so many genetic testing initiatives, all with the goal of customizing treatments for individuals. Now, genetic research into liver cancer revealed a specific mutation, and patients with this disease profile may benefit from 2 different types of drugs already available.
 
Liver cancer is the tenth most common cancer, affecting over 39,000 people every year. Of this, it’s estimated that over 27,000 deaths from liver cancer will occur this year alone, making it the fifth most common cause of cancer death in men.
 
"Liver cancer is a deadly disease," said Luca Tordella, a postdoctoral scientist at the Imperial College London, and the study’s first author. But because the disease is modulated by different factors, no single treatment is effective for everyone. In particular, Tordella said, “It's important to better classify patients into groups, according to their genes. One advance of personalised medicine is to understand which drug will work best on you, and which on me."
 
Tordella’s team searched through the DNA of 100 people with liver cancer. They zeroed in on genes involved with cell senescence – a state of cellular limbo that prevents cancer from forming.
 
In their quest, the team stumbled on a mutation in the Arid1b gene, which allows cancer cells to bypass the senescence checkpoint. In essence, the mutation lets cells leave limbo and go on dividing uncontrollably – the hallmark of cancer cell progression.
 


This mechanism of liver cancer progression is part of a bigger pathway known as the SWI/SNF complex. "Around 20% of patients with liver cancer have mutations on the genes encoding for components of the SWI/SNF complex. What we suggest is if we treat these people with drugs that target the degradation of nucleotides, they will respond," said Jesus Gil, the study’s senior author. "We plan to continue to research this in the lab to develop treatments to target liver cancer."
 
Importantly, this complex has been successfully targeted by other cancer drugs, namely gemcitabine. This chemotherapy drug has been used to treat non-small cell lung cancer, pancreatic cancer, bladder cancer, and breast cancer.
 

 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
DEC 25, 2019
Drug Discovery & Development
DEC 25, 2019
New Drug to Make Breast Cancer Treatment More Affordable
The US Food and Drug Administration has granted accelerated approval to new breast cancer drug, trastuzumab deruxtecan. The drug’s increasing recogni...
JAN 15, 2020
Clinical & Molecular DX
JAN 15, 2020
Laser microchip picks up cancer markers in urine
A future where patients no longer need to endure expensive, painful and complicated cancer tests could soon become a reality. Researchers have developed a...
JAN 15, 2020
Cancer
JAN 15, 2020
Hope for patients with AML
Research published recently in the medical journal EMBO Molecular Medicine brings hope for leukemia patients with a report that a common and cheap drug may...
FEB 07, 2020
Genetics & Genomics
FEB 07, 2020
Mutations That Lead to Cancer May Occur Decades Before Diagnosis
As our cells age or divide, errors can accumulate in the genome they carry, which can lead to cancer, and a variety of environmental and genetic factors ca...
FEB 09, 2020
Microbiology
FEB 09, 2020
Investigating the Links Between Viruses and Cancer
The Pan-Cancer Analysis of Whole Genomes (PCAWG) has brought over 1,300 scientists together to gain new insights into the genetics of cancer....
FEB 12, 2020
Genetics & Genomics
FEB 12, 2020
Vapers Have Epigenetic Alterations Like Those Seen in Smokers
The activity of genes can be altered with chemical tags that get added to the genome, so-called epigenetic modifications....
Loading Comments...